Novartis’ bid to pump up sales of Entresto beyond $5 billion annually got a boost when a U.S. Food and Drug advisory panel recommended the heart failure medicine be used to treat a different form of the disease.

Cyclerion Therapeutics announced the failure of two separate clinical trials for the same drug on the same day.